Contents

Search

secukinumab (Cosentyx)

Indications: - treatment of moderate-severe plaque psoriasis (FDA-approved Jan 2015) - psoriatic arthritis [3,5] - ankylosing spondylitis [4,5] - hidradenitis suppurativa [6] Dosage: - loading dose of 150-300 mg SQ [3] (psoriatic arthritis) - 150-300 mg SQ for 4 weeks (5 doses), then every 4 weeks * intravenous formulation FDA-approved Adverse effects: - candidiasis (resolves with treatment) - nasopharyngitis - upper respiratory infections - headache - neutropenia (1%) - can cause flares of inflammatory bowel disease [5] Mechanism of action: - fully humanized IgG monoclonal antibody - selectively binds to & inhibits interleukin-17A

Interactions

drug adverse effects of pharmaceutical monoclonal antibodies

General

biological response modifier; immune factor; immunomodulator; biomodulator dermatologic agent pharmaceutical monoclonal antibody

References

  1. Langley RG et al. Secukinumab in plaque psoriasis - Results of two phase three trials. N Engl J Med 2014 Jul 9 PMID: 25007392 http://www.nejm.org/doi/full/10.1056/NEJMoa1314258
  2. Brooks M Medscape: FDA Clears Secukinumab (Cosentyx) for Plaque Psoriasis. http://www.medscape.com/viewarticle/838491 - FDA News Release. January 21, 2015 FDA approves new psoriasis drug Cosentyx http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430969.htm
  3. Kuznar W PsA Structural Damage Inhibited with Secukinumab - Loading dose appears to improve outcomes, researchers say. MedPage Today. Nov 9, 2017 https://www.medpagetoday.com/meetingcoverage/acr/69156 - Mease PJ et al Subcutaneous Secukinumab Inhibits Radiographic Progression in Psoriatic Arthritis: Primary Results from a Large Randomized, Controlled, Double-Blind Phase 3 Study American College of Rheumatology (ACR) 2017; Abstract 17L.
  4. Pavelka K, Kivitz A, Dokoupilova E et al Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017 Dec 22;19(1):285. PMID: 29273067 Free PMC Article
  5. Medical Knowledge Self Assessment Program (MKSAP) 18, 19 American College of Physicians, Philadelphia 2018, 2022
  6. Novartis. Oct 23, 2023 FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade. https://www.novartis.com/us-en/news/media-releases/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade